Physician profile
John Berry
NPI 1194702795
$687,311.55
in general payments reported to CMS, 2019-2025
16 companies · $89K in 2025
The $89K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222K · 2020: $62K · 2021: $69K · 2022: $90K · 2023: $79K · 2024: $76K · 2025: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $166K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $45K · Travel and Lodging: $23K · Food and Beverage: $5,942 · Consulting Fee: $3,651 · Long Term Medical Supply Or Device Loan: $500 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $166,040.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $44,715.00 |
| Travel and Lodging | $22,506.70 |
| Food and Beverage | $5,942.36 |
| Consulting Fee | $3,651.25 |
| Long Term Medical Supply Or Device Loan | $499.98 |
| Education | $210.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $210,334.61 | 2019-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals Lp | $132,756.21 | 2019-2025 | Enhertu, Datroway, Imfinzi |
| Daiichi Sankyo INC. | $117,152.08 | 2020-2025 | Enhertu, Datroway |
| Genentech USA, INC. | $97,365.10 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $60,592.87 | 2019-2024 | Keytruda, Prevymis |
| Genzyme Corporation | $33,059.04 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $24,505.05 | 2019-2024 | |
| Dova Pharmaceuticals | $4,070.46 | 2019-2021 | |
| Epizyme, INC. | $3,639.95 | 2020-2021 | |
| Pfizer INC. | $3,388.80 | 2019 | |
| Janssen Biotech, INC. | $164.94 | 2019-2024 | Darzalex |
| Sanofi-Aventis U.S. LLC | $99.95 | 2020 | |
| Glaxosmithkline, LLC. | $92.23 | 2019 | |
| Jazz Pharmaceuticals INC. | $31.87 | 2025 | |
| Astellas Pharma US INC | $29.77 | 2025 | Padcev |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $28.62 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.